Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

59.42USD
13 Aug 2018
Change (% chg)

$0.11 (+0.19%)
Prev Close
$59.31
Open
$59.57
Day's High
$59.80
Day's Low
$59.24
Volume
1,159,555
Avg. Vol
2,019,715
52-wk High
$70.04
52-wk Low
$49.97

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 30.93 32.76
EPS (TTM): 2.74 -- --
ROI: 18.60 15.07 14.61
ROE: 30.97 16.60 16.33

Merck profit beats, but Keytruda sales fail to impress

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy.

27 Jul 2018

UPDATE 4-Merck profit beats, but Keytruda sales fail to impress

* Keytruda sales edge past rival Opdivo's, analysts' estimate

27 Jul 2018

Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

26 Jul 2018

UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

26 Jul 2018

Bristol-Myers to get negative CHMP opinion on renal cancer drugs

NEW YORK Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer.

26 Jul 2018

Bristol-Myers to get negative CHMP opinion on renal cancer drugs

NEW YORK, July 26 Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer.

26 Jul 2018

Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday posted better-than-expected second-quarter earnings and raised its full-year forecast on strong sales from its blockbuster cancer drug Opdivo and blood thinner Eliquis.

26 Jul 2018

RPT-UPDATE 2-Roche takes Tecentriq hit on survival data

ZURICH, July 19 Roche's hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck.

19 Jul 2018

Roche takes Tecentriq hit on survival data

ZURICH Roche's hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck.

19 Jul 2018

UPDATE 2-Roche takes Tecentriq hit on survival data

* Swiss drugmaker says data may come in 2019 (Adds shares, comments from analysts and background)

19 Jul 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $130.22 -0.53
Pfizer Inc. (PFE.N) $40.81 -0.12
Merck & Co., Inc. (MRK.N) $66.72 +0.65
Sanofi SA (SASY.PA) €73.76 +0.27
AstraZeneca plc (AZN.L) 6,038.00 -14.00
GlaxoSmithKline plc (GSK.L) 1,564.00 +13.20
Eli Lilly And Co (LLY.N) $102.44 +0.19
Roche Holding Ltd. (ROG.S) CHF240.50 +2.35
Roche Holding Ltd. (RO.S) CHF244.80 +1.80

Earnings vs. Estimates